RUSH
2 MO. AMENDED Access DB# 109864

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: *Maury Audet* Examiner #: *79808* **Date:** 12/5/03
Art Unit: *1654* Phone Number: *305-5039* **Serial Number:** 09/909,062
Mail Box & Bldg/Room Locat.: CM1-*11D13; 11D04* Results Format Preferred: *PAPER*

If mor than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Filing Date: 7/2/00 (Prov.)

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Please search the 5 closely related peptide compounds (core 1st 3 if free of the art, no more searching needed. If find core, then search for different R-groups coming off).

Tx, MAURY

[Note - 2 previous searches of elected compound #3 (by Susan Hanks showed compound #3 to be free of the art. Applicant is now seeking to open up to compounds #1-2 & 3-4. Basis for updated search reached (by Susan) so no longer searching]

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable	
Searcher:	NA Sequence (#)		STN	30.2.75
Searcher Phone #:	AA Sequence (#)		Dialog	
Searcher Location:	Structure (#)	1	Questel/Orbit	
Date Searcher Picked Up:	12/5		Dr.Link	
Date Completed:	12/5		Lexis/Nexis	
Searcher Prep & Review Time:	20		Sequence Systems	
Clerical Prep Time:			WWW/Internet	
Online Time:	160		Other (specify)	

PTO-1590 (8-01)

Only Agpal's work

=> d que l16
L12 STR

Broad Search

core structure

Page 1-A

1

Page 1-B
NODE ATTRIBUTES:
NSPEC IS RC AT 5
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE
L14 8 SEA FILE=REGISTRY SSS FUL L12
L16 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L14

=> d l16 ibib abs hitstr

L16 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:90074 HCAPLUS
DOCUMENT NUMBER: 136:151440
TITLE: Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank;

← Inventors

McCormick, Jinping; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Liu, Yi-Tsung; Arasappan, Ashok; Parekh, Tejal; Pinto, Patrick A.; Njoroge, F. George; Ganguly, Ashit K.; Brunck, Terence K.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita
PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008256	A2	20020131	WO 2001-US22826	20010719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003036501	A1	20030220	US 2001-909062	20010719
EP 1301528	A2	20030416	EP 2001-959046	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-220109P P 20000721
WO 2001-US22826 W 20010719

OTHER SOURCE(S): MARPAT 136:151440
GI



I



II

AB Novel peptides I [Z = O, NH or substituted imino; X = (un)substituted alkylsulfonyl, heterocyclylsulfonyl, heterocyclylalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylcarbonyl, heterocyclylcarbonyl, heterocyclylalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, heterocyclyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkyaminocarbonyl, heterocyclylaminocarbonyl, arylaminocarbonyl, or heteroarylaminocarbonyl; X1 = H, alkyl, arylmethyl; P1a, P1b, P2-P6 = H, (un)substituted alkyl, alkenyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; P1a and P1b may optionally be joined to each other to form a spirocyclic or spiroheterocyclic ring contg. 0-6 oxygen, nitrogen, sulfur, or phosphorus atoms; P1' = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl] having HCV protease inhibitory activity are disclosed. Thus, peptide II was prepd. via peptide coupling in soln. and showed Ki = 1-100 nM for inhibition of HCV protease.

IT **393520-87-1P 393520-89-3P 393520-91-7P 393521-72-7P 394203-33-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393520-87-1 HCAPLUS

CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393520-89-3 HCAPLUS

CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, 2-(1,1-dimethylethyl) ester, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393520-91-7 HCAPLUS
CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393521-72-7 HCAPLUS
CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 394203-33-9 HCAPLUS
CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **393524-55-5P 393524-57-7P 394203-35-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393524-55-5 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 393524-57-7 HCAPLUS
CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394203-35-1 HCAPLUS
CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

MARPAT

L12 STR



Broad Search

↖ Core Structure

Page 1-A

1

Page 1-B
NODE ATTRIBUTES:
NSPEC IS RC AT 5
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE
L18 2 SEA FILE=MARPAT SSS FUL L12
L19 1 SEA FILE=MARPAT ABB=ON PLU=ON L18/COM

=> d l19 ibib abs fqhit

Same Record as found in HCAPLUS

L19 ANSWER 1 OF 1 MARPAT COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 136:151440 MARPAT
TITLE: Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Liu, Yi-Tsung; Arasappan, Ashok;

Parekh, Tejal; Pinto, Patrick A.; Njoroge, F. George; Ganguly, Ashit K.; Brunck, Terence K.; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita
PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008256	A2	20020131	WO 2001-US22826	20010719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003036501	A1	20030220	US 2001-909062	20010719
EP 1301528	A2	20030416	EP 2001-959046	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-220109P 20000721
WO 2001-US22826 20010719

GI



I



II

AB Novel peptides I [Z = O, NH or substituted imino; X = (un)substituted alkylsulfonyl, heterocyclylsulfonyl, heterocyclylalkylsulfonyl,

arylsulfonyl, heteroarylsulfonyl, alkylcarbonyl, heterocyclylcarbonyl, heterocyclylalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, alkoxycarbonyl, heterocyclyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkyaminocarbonyl, heterocyclylaminocarbonyl, arylaminocarbonyl, or heteroarylaminocarbonyl; X1 = H, alkyl, arylmethyl; P1a, P1b, P2-P6 = H, (un)substituted alkyl, alkenyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; P1a and P1b may optionally be joined to each other to form a spirocyclic or spiroheterocyclic ring contg. 0-6 oxygen, nitrogen, sulfur, or phosphorus atoms; P1' = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl] having HCV protease inhibitory activity are disclosed. Thus, peptide II was prepd. via peptide coupling in soln. and showed Ki = 1-100 nM for inhibition of HCV protease.

MSTR 1



G1 = 84



G2 = 88



G3 = Me
G12 = 200-17 354-21



G13 = 162



G16 = 117





G17 = (1-4) CH2
G20 = Pr-i / cyclopropyl
G29 = 188



G30 = S
G33 = Pr-n
G53 = 11-10 16-17



G55 = S
G7 +G21= 179-14 181-15



MPL: claim 1
NTE: and pharmaceutically acceptable salts, solvates, derivatives and tautomers
NTE: substitution is restricted
NTE: also incorporates claim 16
STE: enantiomers, stereoisomers, and rotomers

Update

L Number	Hits	Search Text	DB	Time stamp
3	2	200009543.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:13
4	4	381216.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:16
5	7	8904669.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:15
6	0	381216.pn. and hepatitis	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:16
7	0	5607912.pn. and hepatitis	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:17
8	2	5514694.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:17
9	0	5514694.pn. and hepatitis	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:17
10	2	5488067.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:27
13	2	200174768.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:55
14	1	200140262.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:28
15	1	200052032.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:35
16	4	2362911.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:44
17	10	Takemura.in. and hepatitis	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:34
18	11182	Takemura.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:34
19	1	200052032.pn. and prolinamide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:35
20	1	200052032.pn. and elastase	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:35
21	1	200052032.pn. and inhibitor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:35

22	0	2362911.pn. and takemura.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:35
23	7	514/17.ccls. and protease and inhibitors and NS3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:44
24	5	514/17.ccls. and protease and inhibitors and NS3 and HCV	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:45
25	7	514/17.ccls. and protease and inhibitors and HCV	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:46
26	258	435/6.ccls. and protease and inhibitors and HCV	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:46
27	21	435/6.ccls. and protease SAME inhibitors SAME HCV	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:46
28	4	2362911.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:55
29	2	9817679.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:56
30	3	9964442.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:56
31	3	2778406.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:56
-	2	6251583.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 13:05
-	2	6265380.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 08:55
-	2	5990276.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 09:28
-	2	9718968.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 09:28
-	2	9718968.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/19 09:28
-	2	9817679.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:36
-	3151	"hepatitis C virus"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:37

-	1333	"hepatitis C virus".ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:37
-	970	"hepatitis C virus".ti.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:38
-	1483	HCV.ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:38
-	134	"HCV protease"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:39
-	52	"HCV protease".ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:39
-	121	"HCV protease" and inhibitor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:39
-	32	"HCV protease".ab. and inhibitor.ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:40
-	6	"HCV inhibitor".ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:40
-	36	"NS3/NS4a"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:44
-	0	"NS-3/NS4a"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:44
-	11	"NS3/NS4a".ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:46
-	172	"HCV polypeptide"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:45
-	93	"HCV peptide"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:45
-	276	"HCV protein"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 04:45
-	10	"NS3/NS4a".ab. and inhibitor.ab.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:08
-	0	"NS3/NS4a".ab. and inhibitor.ab. and 435/6.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:08
-	0	"NS3/NS4a".ab. and inhibitor.ab. and 435/5.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:09

-	0	"NS3/NS4a".ab. and 435/5.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:09
-	9	"NS3/NS4a" and 435/5.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:09
-	0	"NS3/NS4a".ab. and 435/6.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:09
-	0	"NS3/NS4a".ab. and 435/23.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:09
-	6	"NS3 protease" and inhibitor and 514/18.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:10
-	22	"NS3 protease" and inhibitor and 435/6.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:10
-	0	"NS3 protease".ab. and inhibitor.ab. and 435/6.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:10
-	2	"NS3 protease".ab. and inhibitor.ab. and 435/5.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:10
-	0	"NS3 protease".ab. and inhibitor.ab. and 435/6.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
-	0	"NS3 protease".ab. and inhibitor.ab. and 514/18.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
-	0	"NS3 protease".ab. and inhibitor.ab. and 514/16.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
-	0	"NS3 protease".ab. and inhibitor.ab. and 514/9.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
-	0	"NS3 protease".ab. and inhibitor.ab. and 514/160.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
-	0	"NS3 protease".ab. and inhibitor.ab. and 424/85.4.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:11
-	1	"NS3 protease".ab. and inhibitor.ab. and 530/324.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:12
-	0	"NS3 protease".ab. and inhibitor.ab. and 530/325.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:12
-	2	"NS3 protease".ab. and inhibitor.ab. and 530/326.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:13

-	2	"NS3 protease".ab. and inhibitor.ab. and 530/329.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:13
-	2	"NS3 protease".ab. and inhibitor.ab. and 530/332.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:13
-	2	"NS3 protease".ab. and inhibitor.ab. and 530/327.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:14
-	1	"NS3 protease".ab. and inhibitor.ab. and 530/328.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:14
-	2	"NS3 protease".ab. and inhibitor.ab. and 435/23.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:14
-	3	"NS3 protease".ab. and inhibitor and 435/5.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/03/20 05:15
-	7	8904669.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 13:07
-	2	9817679.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 13:08
-	2	200009558.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/12/05 15:11